DB
KRYS icon

Dmitry Balyasny’s Krystal Biotech KRYS Stock Holding History

Dmitry Balyasny’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59,810
Closed -$11.5M – 2962
2024
Q2 		$11M Sell
59,810
-64,393
-52% -$10.8M 0.02% 842
2024
Q1 		$22.1M Sell
124,203
-132,401
-52% -$18.4M 0.04% 573
2023
Q4 		$31.8M Buy
256,604
+223,962
+686% +$24.8M 0.06% 425
2023
Q3 		$3.79M Sell
32,642
-3,948
-11% -$482K 0.01% 1196
2023
Q2 		$4.3M Sell
36,590
-4,545
-11% -$464K 0.01% 1116
2023
Q1 		$3.29M Buy
41,135
+32,759
+391% +$2.57M 0.01% 1239
2022
Q4 		$664K Buy
+8,376
New +$622K ﹤0.01% 1790

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Dmitry Balyasny's KRYS Position: Q3 2024 in Review

Dmitry Balyasny sold out of Krystal Biotech (KRYS) in Q3 2024, closing a stake of 59,810 shares — an estimated $11.5M sold.

Dmitry Balyasny first reported a position in KRYS in Q4 2022 and held it in 7 quarters. The position peaked at $31.8M in Q4 2023. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Dmitry Balyasny reported no remaining Krystal Biotech position as of Q3 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 59,810 Krystal Biotech shares in Q3 2024, an estimated $11.5M.
  • Dmitry Balyasny first reported a position in Krystal Biotech in Q4 2022 and held it in 7 quarters.
  • Dmitry Balyasny's Krystal Biotech position peaked at $31.8M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.